News & Perspective

Nov 06, 2001

Nov 06, 2001

D. A. Henderson to direct new Office of Public Health Preparedness

(CIDRAP News) – Donald A. Henderson, MD, public health expert and director of the successful campaign to eradicate smallpox in the 1970s, has been appointed to coordinate the national response to public health emergencies. Tommy G. Thompson, secretary of the Department of Health and Human Services (HHS), named Henderson last week as director of the newly created Office of Public Health Preparedness.

Dec 05, 2001

Dec 05, 2001

Quarantine not likely to be best tool for halting bioterrorism-related disease, experts say

(CIDRAP News) – Large-scale quarantine of potentially exposed people is not likely to be the optimal strategy for containing a disease outbreak resulting from bioterrorism in most circumstances, according to public health experts writing in today's issue of the Journal of the American Medical Association.

Dec 10, 2001

Dec 10, 2001

HHS announces new bioterrorism research initiatives

(CIDRAP News) – The US Department of Health and Human Services (HHS) has announced seven new research grant programs to speed efforts to prevent, diagnose, and treat diseases related to bioterrorism.

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Dec 21, 2001

Dec 21, 2001

FDA completes inspection of anthrax vaccine plant; company expects approval

(CIDRAP News) – The Food and Drug Administration (FDA) has completed a new inspection of BioPort Corp., the only US manufacturer of the anthrax vaccine, and a company official is predicting approval of the facility after a few remaining concerns are ironed out.

Feb 01, 2002

Feb 01, 2002

FDA clears BioPort to distribute anthrax vaccine

(CIDRAP News) – BioPort Corp of Lansing, Mich., yesterday received Food and Drug Administration (FDA) approval to begin routine distribution of its anthrax vaccine after more than 3 years of effort to bring its operation up to federal standards.

"FDA is now satisfied that BioPort's renovated facility can produce a vaccine that meets FDA standards for safety and efficacy," the agency said in a news release.

Feb 06, 2002

Feb 06, 2002

Proposed 2003 HHS budget includes a 45% boost in bioterrorism-related spending

(CIDRAP News) – The proposed 2003 budget for the US Department of Health and Human Services (HHS) features a 45% increase in spending for bioterrorism preparedness, with research at the National Institutes of Health (NIH) accounting for much of the increase.

May 14, 2002

May 14, 2002

CDC to hear from the public on smallpox vaccination issues

Federal health authorities provide opportunities in the next month for input as they revise the current policy regarding vaccination of the general population.

Jun 13, 2002

Jun 13, 2002

New bioterrorism law aims to boost public health, guard food and water

(CIDRAP News) – President George W. Bush yesterday signed a far-reaching bioterrorism bill designed to strengthen the public health system, tighten controls on dangerous pathogens, and protect the nation’s food and water supplies.

 

Jul 01, 2002

Jul 01, 2002

Pentagon will turn over part of anthrax vaccine supply for civilian use

July 1, 2002 (CIDRAP News) – About half of the nation's supply of anthrax vaccine—previously dedicated almost entirely to military use—will henceforward be set aside for civilian use in the event of another anthrax attack, federal defense and health officials announced Jun 28.

Pages

by Topic

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M logo Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»